Literature DB >> 7911015

Activation of soluble guanylyl cyclase by a factor other than nitric oxide or carbon monoxide contributes to the vascular hyporeactivity to vasoconstrictor agents in the aorta of rats treated with endotoxin.

C C Wu1, C Szabó, S J Chen, C Thiemermann, J R Vane.   

Abstract

We have examined the role of soluble guanylyl cyclase and possible mediators of its activation in the vascular hyporeactivity caused by bacterial endotoxin (lipopolysaccharide, LPS) ex vivo. Treatment of rats with E. coli LPS (10 mg/kg, i.v. for 3h) resulted in a significant reduction in the contractions elicited by norepinephrine (NE; 10(-9)-10(-6) M) in endothelium-denuded aortic rings ex vivo. Methylene blue or LY-83583, inhibitors of soluble guanylyl cyclase, completely restored contractions to NE, whereas the nitric oxide synthase (NOS) inhibitor, N omega-nitro-L-arginine methyl ester (L-NAME), caused only a partial restoration. Zinc protoporphyrin-IX, an inhibitor of heme oxygenase, did not enhance NE-induced contraction in rings from LPS-treated rats, indicating that the production of carbon monoxide (CO) does not contribute to this vascular hyporeactivity. Indomethacin, an inhibitor of cyclooxygenase, further suppressed the contractions in rings from LPS-treated rats. These results suggest that hyporesponsiveness to NE caused by LPS is due to the activation of soluble guanylyl cyclase, which is partially mediated by N(O), but not by CO. Moreover, LPS may induce the production of another mediator(s) that activate soluble guanylyl cyclase in the vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7911015     DOI: 10.1006/bbrc.1994.1720

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Increased activity of guanylate cyclase in the atherosclerotic rabbit aorta: role of non-endothelial nitric oxide synthases.

Authors:  A Rupin; D Behr; T J Verbeuren
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia.

Authors:  C Szabó; G Haskó; B Zingarelli; Z H Németh; A L Salzman; V Kvetan; S M Pastores; E S Vizi
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

3.  Inhibition of endotoxin-induced vascular hyporeactivity by 4-amino-tetrahydrobiopterin.

Authors:  H D Gibraeil; P Dittrich; S Saleh; B Mayer
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

4.  Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock.

Authors:  C C Wu; S J Chen; C Szabó; C Thiemermann; J R Vane
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

5.  Different mechanism of LPS-induced vasodilation in resistance and conductance arteries from SHR and normotensive rats.

Authors:  Nelson C Farias; Gisele L Borelli-Montigny; Grasiele Fauaz; Teresa Feres; Antonio C R Borges; Therezinha B Paiva
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

6.  Spontaneous rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform.

Authors:  G J Southan; B Zingarelli; M O'Connor; A L Salzman; C Szabó
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

7.  Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat.

Authors:  C C Wu; J D Croxtall; M Perretti; C E Bryant; C Thiemermann; R J Flower; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 8.  Carbon monoxide in intensive care medicine-time to start the therapeutic application?!

Authors:  Ulrich Goebel; Jakob Wollborn
Journal:  Intensive Care Med Exp       Date:  2020-01-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.